Doximity Q4 Earnings Miss, 8% Drop

Doximity posted Q4 FY2026 adjusted EPS of $0.26, missing $0.28 estimates, triggering an 8% after‑hours share fall.
Revenue reached $145.4 million, slightly above consensus $144.07 million and up 5% YoY, while adjusted EBITDA fell 6% to $65.8 million, margin 45.3%.
FY2026 revenue rose 13% to $644.9 million, net income $302.7 million (46.9% margin), and cash flows $326.5 million operating, $317.5 million free, both up 19% YoY.
Doximity announced partnerships with Aledade and Photon, reached 800,000 active prescribers, and appointed Matt Sonefeldt CFO and Dr. Steve Zatz President.